CYSTIC TRANSFORMATION OF NEUROENDOCRINE TUMORS

Developmental trends in targeted radionuclide therapy of neuroendocrine tumors

  Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms including carcinoids, pancreatic neuroendocrine tumors, pituitary tumors, medullary thyroid carcinoma and phaeochromocytomas. The symptoms and the outcome of NETs differ considerably between patients depending on several factors. By labelling tracers with a radioisotope, the tracer acts as a ...

Neuroendocrine tumors.

Neuroendocrine tumors comprise a broad family of tumors, the most common of which are carcinoid and pancreatic neuroendocrine tumors. The NCCN Neuroendocrine Tumors Guidelines discuss the diagnosis and management of both sporadic and hereditary neuroendocrine tumors. Most of the recommendations pertain to well-differentiated, low- to intermediate-grade tumors. This updated version of the NCCN G...

Neuroendocrine Tumors

Nalân Utku1* and Ulrich Frank Pape2 1Campus Virchow Institute for Medical Immunology, Institutsgebäude Süd Föhrer, 213353 Berlin, Germany 2Campus Mitte and Virchow, Charité Comprehensive Cancer Center and Gastrophatology2, Charite, Berlin, Germany *Corresponding author: Nalân Utku, Campus Virchow Institute for Medical Immunology, Institutsgebäude Süd Föhrer, 213353 Berlin, Germany; E-mail: nala...

Theranostics of Neuroendocrine Tumors.

Somatostatin receptor positron emission tomography/computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefit...

Bronchial Neuroendocrine Tumors